Karyopharm Therap (KPTI) Misses Q2 EPS by 52c

Karyopharm Therap (NASDAQ: KPTI) reported Q2 EPS of ($1.02), $0.52 worse than the analyst estimate of ($0.50). Revenue for the quarter came in at $21 thousand versus the consensus estimate of $150 thousand.

For earnings history and earnings-related data on Karyopharm Therap (KPTI) click here.

You May Also Be Interested In

• Piper Sandler sees Google TPU sales hitting $104BN by 2028
• Jefferies Financial Group (JEF) Tops Q3 EPS by 8c
• Prabhudas Lilladher Starts Aditya Birla Sun Life AMC (ABSLAMC:IN) at Buy (1)